1. Background
Sucralfate Tablets USP 1 g are an oral gastrointestinal medication primarily used in the prevention and treatment of duodenal ulcers, gastric ulcers, and conditions associated with excess stomach acid. The product works by forming a protective barrier over ulcerated tissue, shielding it from gastric acid.
Manufacturer: Nostrum Laboratories, Inc., a U.S.-based pharmaceutical company known for producing a range of generic medications.
FDA Recall Classification: Class II – a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, and the probability of serious adverse health consequences is remote.
2. The Incident
On July 11, 2025, Nostrum Laboratories announced a voluntary nationwide recall of all in-expiry lots of Sucralfate Tablets USP 1 g, manufactured after June 2023.
The recall was initiated because the company could no longer assure the product’s identity, strength, quality, and purity due to the complete shutdown of its operations and absence of quality control personnel.
3. Timeline
| Date | Event |
|---|---|
| June 2023 | Manufacturing of the affected product lots begins. |
| Sept 30, 2024 | Nostrum Laboratories files for Chapter 11 bankruptcy and halts all U.S. operations. Quality control teams are terminated. |
| July 11, 2025 | Company officially issues voluntary recall notice to customers and distributors. |
| July 14, 2025 | FDA posts recall announcement on its public website. |
4. Why Did This Happen?
- Operational Shutdown: Bankruptcy led to closure of production facilities and termination of quality oversight.
- Loss of Quality Assurance: Without ongoing stability testing and QC programs, the company could not guarantee that products met FDA-mandated specifications for identity, strength, quality, and purity through their labeled shelf life.
- Regulatory Compliance Obligation: As per FDA regulations, manufacturers must recall products if quality cannot be assured—even if no contamination or defects have yet been identified.
5. Who Is Involved?
- Manufacturer: Nostrum Laboratories, Inc.
- Regulatory Body: U.S. Food and Drug Administration (FDA).
- Distribution Network: U.S.-wide distribution to wholesalers, retailers, medical facilities, manufacturers, and repackagers.
- End Users: Patients prescribed Sucralfate for ulcer prevention and treatment; also used in some veterinary medicine applications.
6. What Products Are Affected?
- Drug Name: Sucralfate Tablets USP 1 g
- Dosage Form: Oral tablet
- Packaging:
- NDC 29033-0003-01: 100-count bottles
- NDC 29033-0003-05: 500-count bottles
- Recall Quantity: 60,608 bottles across all lots in expiry
- Distribution: Nationwide, United States
7. How Was the Recall Carried Out?
- Notification: Distributors and direct consignees were notified via email and U.S. mail.
- Instructions:
- Stop distribution immediately.
- Destroy all remaining in-expiry stock.
- Notify downstream customers, retailers, and end users.
- Returns: No product returns accepted due to operational shutdown.
- Public Advisory: FDA recall notice advised consumers to consult healthcare providers before stopping medication.
8. Impact
- On Patients:
- No adverse events reported to date.
- Possible—but unconfirmed—risk of reduced drug potency or quality over time.
- On Supply Chain:
- Short-term shortage potential in some regions for Sucralfate prescriptions.
- Increased pressure on alternative generic suppliers to fill demand.
- On Company:
- Reputational damage.
- Regulatory and legal liabilities post-bankruptcy.
- On Industry:
- Highlights vulnerability of supply chains when smaller manufacturers face financial collapse.
9. Risk Assessment
- Immediate Risk: Low likelihood of serious adverse events due to nature of the drug and Class II classification.
- Potential Risk: In absence of quality control, risks include potency degradation, contamination, or impurity formation over time.
10. Lessons Learned
- Business Stability Directly Affects Drug Safety: Manufacturer bankruptcy can disrupt not just production but also post-market quality assurance.
- Quality Systems Must Be Maintained Until Last Unit’s Expiry: Even after manufacturing stops, companies are legally obligated to continue stability monitoring.
- Regulatory Compliance Extends Beyond Active Operations: Obligations persist as long as products are in the market.
- Transparent Communication Builds Trust: Nostrum’s recall notice and cooperation with FDA minimized confusion among distributors and patients.
11. Conclusion
This recall was preventive rather than reactive—no contamination or patient harm was identified at the time of the recall. However, by proactively recalling the product, Nostrum Laboratories complied with regulatory obligations, potentially preventing patient risk from undetected quality degradation.
It also serves as a critical industry reminder: financial insolvency does not exempt a company from post-market responsibilities.
Discover more from सुदर्शन
Subscribe to get the latest posts sent to your email.